Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals
Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.
In this Pharmaceutical Executive podcast episode, UpScriptHealth founder and CEO Peter Ax discusses:
- The impact of tariffs on the pharmaceutical industry, highlighting branded and generics medications
- How tariffs could lead to strategic supply chain changes, including potential US manufacturing shifts
- How digital health platforms can help potentially offset tariff impacts
- The importance of telehealth in ensuring medication availability
- Strategic partnerships between digital health platforms and pharma companies to improve patient care and access
- and more
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
FDA Approves Celltrion’s Xolair Biosimilar Omlyclo for Multiple Indications
March 10th 2025Omlyclo, a biosimilar to Xolair, is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, immunoglobulin E-mediated food allergies, and chronic spontaneous urticaria.
